Aromasin® Non-Interventional Study Of Early Invasive Breast Cancer Patients In China
Conditions
Breast Neoplasms
Conditions: official terms
Breast Neoplasms
Conditions: Keywords
breast cancer, Aromasin, adjuvant chemotherapy, endocrine therapy
Study Type
Observational
Study Phase
N/A
Study Design
Time Perspective: Prospective
Intervention
Name: Aromasin (exemestane)
Type: Drug
Overall Status
Recruiting
Summary
Aromasin® (Exemestane) was approved in China for adjuvant treatment of postmenopausal women with estrogen receptor (ER) positive early invasive breast cancer who have received 2-3 years of tamoxifen & are switched to Aromasin® for completion of a total of 5 consecutive years of adjuvant hormonal therapy by State Food and Drug Administration (SFDA) with clinical trial waive. While Aromasin® has been used in China for adjuvant therapy of breast cancer since then, there is currently lack of systematic collection and analysis for the efficacy and safety data of Aromasin® adjuvant setting in Chinese population. The Aromasin® Non-Interventional Study is being proposed to collect data systematically and to assess the efficacy and safety of Aromasin® adjuvant setting in Chinese population.
Detailed Description
This is non-interventional study and single arm study. N/A
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Female
Criteria: Inclusion Criteria:

- Early invasive breast cancer (T1-4N1-3M0) confirmed by histology or cytology.

- ER positive.

- The patient must be postmenopausal woman.

- The patient has received adjuvant Tamoxifen therapy for up to 2-3 years and will switch to receive Aromasin® treatment (The decision to prescribe Aromasin® will necessarily precede and will be independent of the decision to enroll patients in the study).

Exclusion Criteria:

- Following the adjuvant Tamoxifen therapy for 2-3 years and prior to receiving Aromasin® treatment, there is evidence of a local relapse or distant metastasis of breast cancer, or a second primary cancer.

- Following the adjuvant Tamoxifen therapy for 2-3 years and received other aromatase inhibitors (not Aromasin®).
Locations
The First Affiliated Hospital of Bengbu Medical College/Medical Oncology Department
Bengbu, Anhui, China
Status: Recruiting
The Second Affiliated Hospital of Anhui Medical University, Oncology Dept.
Hefei, Anhui, China
Status: Recruiting
Beijing Cancer Hospital
Beijing, Beijing, China
Status: Recruiting
The First Hospital Affiliated to Chongqing Medical University
Chongqing, Chongqing, China
Status: Recruiting
The First hospital of LanZhou university
Lanzhou, Gansu, China
Status: Recruiting
The Second Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Status: Recruiting
Cancer Hospital of Shantou University Medical College
Shantou, Guangdong, China
Status: Recruiting
ShenZhen Second Hospital/Department of Breast Surgery
Shenzhen, Guangdong, China
Status: Recruiting
Affiliated hospital of Guangdong medical college
ZhanJiang, Guangdong, China
Status: Recruiting
Breast Surgery of Hainan General Hospital
Haikou, Hainan, China
Status: Recruiting
Surgery department of Hebei Cancer Hospital
Shijiazhuang, Hebei, China
Status: Recruiting
Breast Department of Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Status: Recruiting
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China
Status: Recruiting
Henan provincial people's hospital
Zhengzhou, Henan, China
Status: Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Status: Recruiting
Henan Cancer Hospital
Zhenzhou, Henan, China
Status: Recruiting
Jingzhou Hospital Tongji Medical College Huazhong university of science and Technology
Jingzhou, Hubei, China
Status: Recruiting
Breast and thyroid surgery Department
Changsha, Hunan, China
Status: Recruiting
Xiangya Hospital Centre-South University /Department of Breast
Changsha, Hunan, China
Status: Recruiting
The Affiliated Hospital of inner Mongolia medical college
Hu he hao te, Inner Mongolia, China
Status: Recruiting
Jiangsu Province Hospital/ Surgery Department
Nanjing, Jiangsu, China
Status: Recruiting
Jiansu Cancer Hospital/ Surgery Department
Nanjing, Jiangsu, China
Status: Recruiting
Nanjing General Hospital of Nanjing Military Command
Nanjing, Jiangsu, China
Status: Recruiting
Suzhou Municipal Hospital
Suzhou, Jiangsu, China
Status: Recruiting
The first hospital of jilin university
Changchun, Jilin, China
Status: Recruiting
The First Affiliated Hospital of Xi'an Jiaotong University/Oncology Surgery
Xi'an, Shaanxi, China
Status: Recruiting
Xijing Hospital
Xi'an, Shaanxi, China
Status: Recruiting
Qingdao municipal hospital
Qingdao, Shandong, China
Status: Recruiting
Sichuan Provincial People's Hospital
Chendu, Sichuan, China
Status: Recruiting
The Second People's Hospital of Sichuan
Chengdu, Sichuan, China
Status: Recruiting
Breast surgery of The Affiliated Hospital of North Sichuan Medical College
NanChong, Sichuan, China
Status: Recruiting
Xinjiang Cancer Hospital
Urumqi, Xinjiang, China
Status: Recruiting
Zhejiang Cancer Hospital/Breast Oncology
Hangzhou, Zhejiang, China
Status: Recruiting
307 Hospital of PLA
Beijing, China
Status: Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Science and Peking Union Medical College
Beijing, China
Status: Recruiting
China-Japan Friendship Hospital
Beijing, China
Status: Recruiting
Peking University Third Hospital/Department of Oncology
Beijing, China
Status: Recruiting
Breast Surgery of Changzhou No.2 People's Hospital
Chang Zhou, China
Status: Recruiting
West China Hospital, Sichuan University/ Thyroid & Breast Department
Chengdu, China
Status: Recruiting
Breast Surgery of The Second Affiliated Hospital of Guangzhou Medical University
Guang Zhou, China
Status: Recruiting
The First Affiliated Hospital of Anhui Medical University
Hefei, China
Status: Recruiting
The Affiliated Hospital of Medical College Qingdao University
Qingdao, China
Status: Recruiting
Fudan University Shanghai Cancer center/Department of Breast Surgery
Shanghai, China
Status: Recruiting
Yangpu District Central Hospital
Shanghai, China
Status: Recruiting
Tianjin Oncology Hospital /Department of Breast Surgery
Tianjin, China
Status: Recruiting
Breast and thyroid surgery of Central Hospital of Zibo
Zibo, China
Status: Recruiting
Start Date
February 2011
Completion Date
October 2019
Sponsors
Pfizer
Source
Pfizer
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page